HEV assay

Patent metadata

Field	Value
Publication number	US-9702017-B2
Application number	US-201313864439-A
Country	US
Kind code	B2
Filing date	Apr 17, 2013
Priority date	Apr 18, 2012
Publication date	Jul 11, 2017
Grant date	Jul 11, 2017

Abstract

A method of simultaneously amplifying genotypes 1, 2, 3 and/or 4 of HEV is disclosed comprising amplifying the genotypes 1, 2, 3 and/or 4 of HEV with one single none-degenerate forward primer partially overlapping the 5′UTR region of HEV and at least one reverse primer. Also disclosed are related methods comprising a probe, and kits for the detection of genotypes 1, 2, 3 and/or 4 of HEV.

First claim

What is claimed is:

1. A method for simultaneously detecting the presence or absence of genotypes 1, 2, 3, and/or 4 of hepatitis E virus (HEV) in a biological sample, comprising the steps of:
(a) isolating nucleic acids present in the biological sample;
(b) amplifying the nucleic acids isolated in step (a) in a single reaction mixture, using one non-degenerate forward primer comprising SEQ ID NO: 6 and at least one non-degenerate reverse primer comprising a sequence selected from the group consisting of SEQ ID NOS: 11, 13, and 14, wherein the forward and reverse primers simultaneously amplify genotypes 1, 2, 3, and/or 4 of HEV, if present in the biological sample; and
(c) detecting the presence or absence of amplified nucleic acid obtained in step (b), wherein the presence of amplified nucleic acid obtained in step (b) is an indication of the presence of genotypes 1, 2, 3, and/or 4 of HEV in the biological sample, and wherein the absence of amplified nucleic acid obtained in step (b) is an indication of the absence of genotypes 1, 2, 3, and/or 4 of HEV in the biological sample.

2. The method of claim 1 , wherein the forward primer comprises SEQ ID NO: 6 and the at least one reverse primer comprises a sequence selected from the group consisting of SEQ ID NOS: 13 and 14.

3. The method of claim 1 , wherein the amplifying step (b) uses at least two non-degenerate reverse primers comprising the sequences of SEQ ID NOS: 13 and 14, and wherein the forward primer comprises SEQ ID NO: 6.

4. The method of claim 1 , wherein said isolating step (a) comprises binding the nucleic acids to a solid phase.

5. The method of claim 1 , wherein the amplified nucleic acids are contacted with a nucleic acid probe under conditions sufficient for binding the probe to the amplified nucleic acids.

6. The method of claim 5 , wherein the probe comprises at least 20 contiguous nucleotides of SEQ ID NOS: 15-19, or the complementary sequence thereof.

7. The method of claim 5 , wherein the probe comprises at least 22 to 35 contiguous nucleotides of SEQ ID NOS: 15-19, or the complementary sequence thereof.

8. The method of claim 5 , wherein the probe consists of a sequence selected from SEQ ID NOS: 15-19, or the complementary sequence thereof.

9. The method of claim 5 , wherein the probe consists of a sequence selected from SEQ ID NO: 15-18.

10. The method of claim 5 , wherein the probe comprises a fluorophore and a quencher.

11. The method of claim 10 , wherein the fluorophore is coupled to the 5′ end of the probe, and the spacing between the fluorophore and the quencher comprises at least 9 nucleotides.

12. The method of claim 1 , wherein the forward primer comprises SEQ ID NO: 6 and the at least one reverse primer comprises SEQ ID NO: 11.

13. The method of claim 1 , further comprising the step of: (c) detecting amplified nucleic acids obtained in step (b) as an indication of the presence of genotypes 1, 2, 3, and 4 of HEV in the biological sample.

14. The method of claim 13 , wherein the amplified nucleic acids are contacted with a nucleic acid probe under conditions sufficient for binding the probe to the amplified nucleic acids.

15. The method of claim 14 , wherein the probe comprises at least 20 contiguous nucleotides of SEQ ID NOS: 15 or 18, or the complementary sequence thereof.

16. The method of claim 14 , wherein the probe comprises at least 22 to 35 contiguous nucleotides of SEQ ID NOS: 15 or 18, or the complementary sequence thereof.

17. The method of claim 14 , wherein the probe consists of a sequence selected from SEQ ID NOS: 15 or 18, or the complementary sequence thereof.

18. The method of claim 14 , wherein the probe consists of a sequence selected from SEQ ID NO: 15 or 18.

19. The method of claim 14 , wherein the probe comprises a fluorophore and a quencher.

20. The method of claim 19 , wherein the fluorophore is coupled to the 5′ end of the probe, and the spacing between the fluorophore and the quencher comprises at least 9 nucleotides.

Assignees

• Roche Molecular Systems Inc

Inventors

• Leying Hermann
• Myers Thomas W
• Newton Nicolas
• Russmann Eberhard
• San Filippo Joseph
• Schoenbrunner Nancy
• Wilts Heike
• Wu Xiaoning
• Young Karen K Y
• Zimmermann Dirk

Classifications

• C12Q1/707 Primary

  non-A, non-B Hepatitis, excluding hepatitis D · CPC title

• C12Q2600/16

  Primer sets for multiplex assays · CPC title